Here's Why Cue Biopharma (CUE) is Poised for a Turnaround After Losing -22.83% in 4 Weeks [Yahoo! Finance]
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]
Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now [Yahoo! Finance]
Cue Biopharma, Inc. (NASDAQ: CUE) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $8.00 price target on the stock.